Calyxo Enters AUA2026 With Its Largest Clinical Evidence Presence to Date and Enhanced Visualization

Key Takeaways

• 10 abstracts at AUA 2026, most ever for CVIC System
• Over 40,000 patients treated with CVIC since FDA clearance
• Version 1.5 software improves intra‑operative image clarity and consistency
• Hands‑on workshops let physicians experience high‑performance aspiration technology
• CVIC targets $4.1 billion U.S. kidney‑stone market

Pulse Analysis

Kidney‑stone disease affects roughly one in ten Americans and is projected to generate about $4.1 billion in direct treatment costs by 2030. Traditional lithotripsy and basket extraction methods often require multiple passes and can leave residual fragments, driving repeat procedures and higher expenses. In this context, technologies that combine irrigation, suction, and real‑time visualization are gaining attention for their potential to improve stone‑free rates while reducing operative time and hospital stays. Calyxo’s CVIC System, cleared by the FDA in 2024, directly addresses these challenges by integrating aspiration with laser lithotripsy, offering urologists a single‑device workflow that continuously clears debris and enhances procedural efficiency.

The latest iteration, CVIC Image Processor Software version 1.5, builds on real‑world feedback to sharpen image quality and maintain consistency throughout the case. Clearer visualization is especially critical during laser fragmentation, where precise targeting minimizes collateral tissue damage and maximizes fragment removal. By embedding the software upgrade into the existing hardware platform, Calyxo ensures a seamless transition for operating rooms, preserving established workflows while delivering measurable gains in intra‑operative visibility. Early adopters, such as Mount Sinai’s Dr. Michael Palese, report that the enhanced imaging translates into smoother laser passes and reduced fatigue, underscoring the clinical relevance of incremental software innovation in surgical devices.

Calyxo’s aggressive presence at AUA 2026 underscores its strategy to cement the CVIC System as a standard of care. The ten abstracts—spanning multicenter outcomes, efficiency predictors, and comparative studies—provide a robust evidence base that can sway hospital procurement committees and payer policies. Complementary hands‑on workshops and live demonstrations give physicians tangible experience, accelerating adoption curves. As urology practices seek cost‑effective solutions that improve patient outcomes, Calyxo’s combined hardware‑software proposition positions it to capture a larger share of the lucrative kidney‑stone market, potentially reshaping treatment paradigms across the United States.